Condition: Biochemical Recurrence of Malignant Neoplasm of Prostate · Prostate Cancer · BCR Prostate Carcinoma · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, China | Recruiting |
| Nanfang Hospital Southern Medical University | Guangzhou, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
| West China Hospital of Sichuan University | Sichuan, China | Recruiting |
| Wuhan Union Hospital | Wuhan, China | Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, China | Recruiting |
| Affiliated Hosptial of Jiangnan University | Wuxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05847348